Cilocab® is a preparation of Cilnidipine which is a calcium channel blocker. Cilnidipine is lhe calcium antagoniat accompanied wilh L-lype and N-typo calcium channol blocking function. Cilnidipino can act on the N-lype calcium channel lhal existing aympalhelic nerve end besides acting on L-type calcium channel that similar to most of the calcium
antagonists. It inhibits cellular influx of calcium, thus causing vasodilatation. It has greater selectivity for vascular smooth muscle.
No Data
Cilocab® is indicated for the treatment of hypertension and hypertensive associated vascular disorders.
The recommended adult oral dose of Cilocab® is 5 mg to 10 mg once daily. If needed, the dosage can be increased up to 20 mg.
Pregnancy: There are no adequate studies of cilnidipine in pregnant women to inform whether there is a drug associated risk in pregnancy. However, caution should be exercised during cilnidipine use in pregnancy.
Lactation: It is not known whether cilnidipine is distributed in human breast milk or not However, caution should be exercised during cilnidipine use in lactation.
Hypotension, poor cardiac reserve, heart failure. Sudden withdrawal may exacerbale angina. Discontinue in patients who experience iachemic pain following administration.
Cilnidipine is conlraindicated in patients with known hypersensitivity to cilnidipine or any other components of this product.
Cilnidipine can inleracl with aldesleukin, quinidine, phenyloin, rifarnpicin, erythromycin, other anti-hypertensive drugs and anti-psychotic drugs.
No Data
Store in a cool (below 30° C) and dry place protected from light Keep away from the reach of children.
Cilocab® 5 Tablet: Each coated tablet contains Cilnidipine INN 5 mg.
Cilocab® 10 Tablet: Each coated tablet contains Cilnidipine INN 10 mg.
Cilocab® 5 Tablet: Carton of 30 tablets in blister pack.
Cilocab® 10 Tablet: Carton of 30 tablets in blister pack.